I agree with you muzzarati. A Singapore company revealed >5% ownership of INP and it went up more than 12% on the news.
Phase 2 trials in the US for a more effective common cold treatment got Biota just above the ASX200 increase.
Common cold is incredibly more significant than some dude in Singapore deciding he liked a piece of INP.